Article Summary
A new study has found that a combination shot for flu and COVID-19 using messenger RNA generated antibodies, but U.S. government regulators are seeking data on its protective abilities. Researchers from vaccine-maker Moderna reported the findings in a study published in the journal Nature.
Original Post
A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators want to see data on whether the new vaccine protects people from getting sick. Researchers from vaccine-maker Moderna reported in a study published in the journal Nature that the mRNA vaccine induced immune responses against both the flu and COVID-19 viruses in mice. However, U.S. government regulators have stated that they need to see data on whether the vaccine can protect people from getting sick before approving it for human use.
What This Means for You
- The development of a combination flu and COVID-19 vaccine could simplify the vaccination process and increase compliance.
- It’s still unclear when a combination shot will be available for human use, as further testing and data is required for approval.
- It’s important to continue following public health guidelines and getting vaccinated against both the flu and COVID-19 to protect yourself and others.
- Future research will focus on the efficacy of the combination shot in protecting against both viruses in human trials.
Key Terms
- mRNA vaccine
- COVID-19
- Flu
- Vaccine-maker Moderna
- Combination shot
- U.S. government regulators
- Human trials
ORIGINAL SOURCE:
Source link
